Position in SCLX
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$233
-$193 QoQ
Shares Held
35
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 14%
Shared 0%
None 86%
Common Shares in SCLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026RHUMBLINE ADVISERS holds $4,442,669,436 across 18 Drug Manufacturers - General names. SCLX ranks #18 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,358,698 | $1,249,689,659 | |
| 2 | JNJ |
Johnson & Johnson
|
3,829,150 | $935,997,426 | |
| 3 | ABBV |
AbbVie Inc.
|
2,897,983 | $630,282,322 | |
| 4 | MRK |
Merck & Co., Inc.
|
3,797,430 | $456,792,854 | |
| 5 | AMGN |
Amgen Inc
|
914,016 | $321,596,529 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
2,236,312 | $311,674,803 | |
| 7 | PFE |
Pfizer Inc
|
8,875,485 | $249,223,618 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
3,647,568 | $221,224,999 |
All Filings in SCLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $233 | 35 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $426 | 35 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $688 | 35 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $223 | 38 | Shares | Sole | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||